Phio PharmaceuticalsPHIO -0.97%28 Forward PE Ratio is 0.57 as of Jul. 11, 2026. GuruFocus rates PHIO with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 354 Biotechnology companies, Phio Pharmaceuticals ranks better than 96.33% on this metric.
Phio Pharmaceuticals (NAS:PHIO) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Phio Pharmaceuticals Forward PE Ratio Related Terms
Phio Pharmaceuticals Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Phio Pharmaceuticals's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phio Pharmaceuticals Forward PE Ratio Chart
Phio Pharmaceuticals Annual Data
Trend
2020-12
2021-12
2022-12
2024-12
Forward PE Ratio
1.04
1.02
0.21
0.06
Phio Pharmaceuticals Quarterly Data
2020-09
2020-12
2021-03
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2024-12
2025-03
2025-06
Forward PE Ratio
0.82
1.04
1.22
2.15
1.02
0.92
2.95
0.41
0.21
0.29
0.06
0.34
0.51
PHIO vs PBM, KPRX, OSRH: Forward PE Ratio Comparison
For the Biotechnology subindustry, Phio Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phio Pharmaceuticals Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Phio Pharmaceuticals's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Phio Pharmaceuticals (PHIO) has a Forward PE Ratio of 0.57 as of Jul. 11, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Phio Pharmaceuticals and its competitors. According to the industry distribution chart, Phio Pharmaceuticals ranks #13 out of 354 companies in the Biotechnology industry, placing it in the top 3.7%.
Is Phio Pharmaceuticals' Forward PE Ratio too high?
Phio Pharmaceuticals' current Forward PE Ratio is 0.57. The Biotechnology industry median Forward PE Ratio is 21.90. Phio Pharmaceuticals' value of 0.57 is 97.4% below this industry median. Based on the distribution chart, Phio Pharmaceuticals ranks #13 out of 354 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Phio Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Phio Pharmaceuticals' Forward PE Ratio compare to PBM and KPRX?
According to the Biotechnology industry distribution chart, Phio Pharmaceuticals ranks #13 out of 354 companies for Forward PE Ratio. This places Phio Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 21.90. Phio Pharmaceuticals' value of 0.57 is 97.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.90, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phio Pharmaceuticals's current Forward PE Ratio of 0.57 is 97.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Phio Pharmaceuticals and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phio Pharmaceuticals's current Forward PE Ratio is 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phio Pharmaceuticals stock overvalued right now?
Phio Pharmaceuticals (PHIO) has a current Forward PE Ratio of 0.57. The current Forward PE Ratio is 0.57 and 97.4% below the Biotechnology industry median of 21.90. Phio Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Phio Pharmaceuticals (PHIO), the current Forward PE Ratio is 0.57 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
28GF Score
Get the complete analysis for PHIO
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHIO has been successfully added to your 